Updated:
R1 RCM
R1 RCM runs over $6B in annual revenue recovery for 95 of the top 100 US health systems through an integrated AI + embedded-expert model.
R1 RCM
R1 RCM built its 20-year franchise as the first tech-enabled end-to-end revenue cycle manager for large US health systems, though founding year and original wealth source remain undisclosed. The firm lists a 16-person leadership group headed by Joseph Flanagan and operates from a Chicago headquarters on North Green Street. Its primary client base comprises nearly the entire upper tier of American hospitals, giving it a structural window into provider-unit economics. The firm deploys capital and operating resources across the full revenue cycle, blending agentic AI, automation and embedded human expertise. Its product suite breaks into three named lines—Phare Access, Phare Claim and Phare Flow—layered on a proprietary platform called Phare. The AI-dedicated arm, R37, builds reasoning, language, voice and capture models that target a 5–7 percent yield boost and a 50 percent reduction in cost to collect. Although R1 does not disclose deployment ranges by asset class, its delivery spans end-to-end operating partnerships, modular agentic solutions and physician-focused recovery tools. Client support extends across the US, with at least two named patient-service centers in emergency-department and anesthesiology billing. The investment operation—integrated with the RCM business—covers more than 200 million tasks automated and over $6 billion in annual recovered revenue. R1 maintains customer portals through RevintConnect, MCRC Group and Databound/EMUE. In 2026, the firm launched Phare Audit, an AI-native solution for capturing full reimbursement, and announced a strategic partnership with Sierra to layer AI-driven experiences into healthcare operations. Adjacent activity includes an ESG program that embeds social and sustainable practices into global delivery and corporate culture. R1’s structure is a vertically integrated RCM operator that sells AI and automation to not-for-profit health systems. It competes at the intersection of healthcare IT and revenue management, where most peers act as either software vendors or offshore BPOs—R1 does both and retains onshore operator accountability within the hospital revenue office. That combination gives it a co-sourced model that sits inside provider workflows, not outside them.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Chicago
Corporate office
333 N. Green St. Suite 1100, Chicago, IL 60607, United States
Principals
Joseph Flanagan
Leadership team
John Sparby
Leadership team
Chris Hartemayer
Leadership team
Dave Wojczynski
Leadership team
Chris Ricaurte
Leadership team
Andy Brailo
Leadership team
Steve Albert
Leadership team
Estelle Barnes
Leadership team
Lashana Jackson
Leadership team
Natalie Klotsche
Leadership team
Logan Johnston
Leadership team
Sean Radcliffe
Leadership team
Corey Perman
Leadership team
Dan Bise
Leadership team
Abhijeet Pawar
Leadership team
Cheryl Miller
Leadership team
Sector focus
Frequently asked questions
How does R1 RCM source and deploy capital?
Capital is deployed through the operating business that manages the full revenue cycle for health systems. The model combines upfront investment in automation and AI with recurring revenue from yield improvements and cost reductions. R1 does not operate a traditional fund structure; instead, it enters multiyear operating partnerships where the firm shares in the incremental cash collected.
What is R37, and why does it matter for investment posture?
R37 is R1's dedicated AI lab that develops reasoning, language, voice and capture models for revenue cycle tasks. It functions as an internal R&D engine that produces the agentic software underpinning the firm's Phare platform. This makes technology development a core competency rather than a capability bought from third parties.
Who runs investment and operating decisions at R1?
A 16-person leadership team, led by Joseph Flanagan, directs all investment and operating activity. Specific investment committee structures are not disclosed publicly. Day-to-day execution is spread across technology, operations and client partnership leaders who manage the embedded teams inside hospital systems.
Does R1 RCM invest in external healthcare ventures or just internal capabilities?
The firm's known deployment flows entirely into its own operating model—building Phare product modules, funding the R37 AI lab, and staffing on-site operator teams. The strategic partnership with Sierra signals a willingness to co-develop AI capabilities, but there is no public evidence R1 makes third-party venture investments.
Which metrics best describe R1’s scale?
The firm reports three headline numbers: over $6 billion in annual revenue recovery processed, more than 200 million tasks automated, and partnerships with 95 of the top 100 US health systems. It also claims a 5–7 percent yield boost and a 50 percent reduction in cost to collect for clients, though those figures lack external audit references.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: